scPharmaceuticals (SCPH) Competitors $5.67 0.00 (0.00%) As of 10/7/2025 Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock SCPH vs. CVAC, MAZE, ATAI, CALT, ARDX, SYRE, PHVS, NBTX, PRAX, and RLAYShould you be buying scPharmaceuticals stock or one of its competitors? The main competitors of scPharmaceuticals include CureVac (CVAC), Maze Therapeutics (MAZE), atai Life Sciences (ATAI), Calliditas Therapeutics AB (publ) (CALT), Ardelyx (ARDX), Spyre Therapeutics (SYRE), Pharvaris (PHVS), Nanobiotix (NBTX), Praxis Precision Medicines (PRAX), and Relay Therapeutics (RLAY). These companies are all part of the "pharmaceutical products" industry. scPharmaceuticals vs. Its Competitors CureVac Maze Therapeutics atai Life Sciences Calliditas Therapeutics AB (publ) Ardelyx Spyre Therapeutics Pharvaris Nanobiotix Praxis Precision Medicines Relay Therapeutics scPharmaceuticals (NASDAQ:SCPH) and CureVac (NASDAQ:CVAC) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, media sentiment, risk, dividends, profitability, analyst recommendations, institutional ownership and valuation. Does the media refer more to SCPH or CVAC? In the previous week, scPharmaceuticals had 3 more articles in the media than CureVac. MarketBeat recorded 6 mentions for scPharmaceuticals and 3 mentions for CureVac. CureVac's average media sentiment score of 0.83 beat scPharmaceuticals' score of 0.50 indicating that CureVac is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment scPharmaceuticals 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive CureVac 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more volatility & risk, SCPH or CVAC? scPharmaceuticals has a beta of 0.31, indicating that its share price is 69% less volatile than the S&P 500. Comparatively, CureVac has a beta of 2.51, indicating that its share price is 151% more volatile than the S&P 500. Which has higher earnings & valuation, SCPH or CVAC? CureVac has higher revenue and earnings than scPharmaceuticals. scPharmaceuticals is trading at a lower price-to-earnings ratio than CureVac, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioscPharmaceuticals$49.97M6.05-$85.15M-$1.81-3.13CureVac$579.18M2.08$175.50M$0.965.59 Is SCPH or CVAC more profitable? CureVac has a net margin of 38.21% compared to scPharmaceuticals' net margin of -183.55%. CureVac's return on equity of 29.57% beat scPharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets scPharmaceuticals-183.55% -1,647.86% -71.76% CureVac 38.21%29.57%25.41% Do insiders & institutionals hold more shares of SCPH or CVAC? 89.5% of scPharmaceuticals shares are owned by institutional investors. Comparatively, 17.3% of CureVac shares are owned by institutional investors. 4.8% of scPharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Do analysts rate SCPH or CVAC? scPharmaceuticals currently has a consensus target price of $7.78, indicating a potential upside of 37.27%. CureVac has a consensus target price of $6.83, indicating a potential upside of 27.37%. Given scPharmaceuticals' higher probable upside, research analysts clearly believe scPharmaceuticals is more favorable than CureVac.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score scPharmaceuticals 1 Sell rating(s) 3 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.75CureVac 0 Sell rating(s) 5 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.17 SummaryCureVac beats scPharmaceuticals on 11 of the 16 factors compared between the two stocks. Get scPharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for SCPH and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding SCPH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SCPH vs. The Competition Export to ExcelMetricscPharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$302.20M$3.36B$6.03B$10.43BDividend YieldN/A2.31%5.73%4.82%P/E Ratio-3.1322.0785.1426.98Price / Sales6.05467.02593.69130.89Price / CashN/A44.9825.7730.18Price / Book21.0010.3312.336.67Net Income-$85.15M-$52.47M$3.32B$276.55M7 Day Performance-1.37%-0.42%-0.38%-0.42%1 Month Performance0.71%13.15%8.34%6.58%1 Year Performance35.00%19.48%73.00%40.76% scPharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SCPHscPharmaceuticals4.0087 of 5 stars$5.67flat$7.78+37.3%N/A$302.20M$49.97M-3.1330Analyst UpgradeCVACCureVac3.7396 of 5 stars$5.39+0.2%$6.83+26.8%+85.2%$1.21B$579.18M5.61880MAZEMaze Therapeutics3.2882 of 5 stars$28.57+4.2%$33.83+18.4%N/A$1.20B$167.50M0.00121ATAIatai Life Sciences3.1198 of 5 stars$5.40+5.9%$11.40+111.1%+390.9%$1.19B$310K-7.8380Analyst ForecastCALTCalliditas Therapeutics AB (publ)N/A$40.00flatN/AN/A$1.19B$1.60B-21.62180ARDXArdelyx4.3319 of 5 stars$5.01+1.4%$11.70+133.5%-17.1%$1.19B$333.61M-21.7890News CoverageSYRESpyre Therapeutics2.943 of 5 stars$18.92-1.1%$54.29+186.9%-34.1%$1.16B$890K-5.5673News CoverageAnalyst UpgradePHVSPharvaris2.4753 of 5 stars$22.07+0.4%$32.60+47.7%+11.9%$1.15BN/A-6.5730NBTXNanobiotix1.1938 of 5 stars$30.31+28.4%$11.00-63.7%+512.3%$1.13B$39.18M0.00100Gap DownPRAXPraxis Precision Medicines2.0244 of 5 stars$52.34-1.7%$85.56+63.5%-19.5%$1.12B$8.55M-4.26110RLAYRelay Therapeutics2.5851 of 5 stars$6.27-3.5%$16.50+163.2%-7.8%$1.12B$10.01M-3.22330News Coverage Related Companies and Tools Related Companies CureVac Alternatives Maze Therapeutics Alternatives atai Life Sciences Alternatives Calliditas Therapeutics AB (publ) Alternatives Ardelyx Alternatives Spyre Therapeutics Alternatives Pharvaris Alternatives Nanobiotix Alternatives Praxis Precision Medicines Alternatives Relay Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SCPH) was last updated on 10/14/2025 by MarketBeat.com Staff From Our PartnersThe Army Just Got a New Drone SupplierA cutting-edge drone developer just secured a U.S. Army deal to supply its Flex FPV Modular Drones and build a...The Tomorrow Investor | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredGold to $27,533?This week, U.S. gold reserves hit an unprecedented $1 TRILLION in value... And it's sparking urgent chatter...Stansberry Research | SponsoredRefund From 1933: Trump’s Reset May Create Instant WealthTrump's Reset Can Give Birth To America's Greatest Era Yet A 90-Year cycle may end soon, creating real weal...American Hartford Gold | SponsoredYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredWhat if your job didn’t matter — and neither did China’s chip ban?If you’ve been watching the headlines lately…You’ve seen how Nvidia and AMD just got the green light to resume...Timothy Sykes | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding scPharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share scPharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
